Assisted reproductive technology treatment failure and the detection of intrauterine HPV through spent embryo transfer media sample
© 2024 Wiley Periodicals LLC..
Cervical human papillomavirus (HPV) infection is believed to increase the risks of pregnancy failure and abortion, however, whether the uterine cavity HPV infection reduces pregnancy rate or increases miscarriage rate remains unclarified in infertile women undergoing assisted reproductive technology (ART) treatment. Therefore, we aimed to assess ART outcomes in the presence of intrauterine HPV. This was a hospital-based multicenter (five reproductive medicine centers) matched cohort study. This study involved 4153 infertile women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection treatment in five reproductive medicine centers between October 2018 and 2020. The spent embryo transfer media sample with endometrium tissue were collected and performed with flow-through hybridization and gene chips to detect HPV DNA. According to basic characteristics, HPV-positive and negative patients were matched in a ratio of 1:4 by age, body mass index transfer timing, transfer type, and number of embryos transferred. The primary outcome was pregnancy and clinical miscarriage rates in the transfer cycle underwent HPV detection. 92 HPV-positive and 368 HPV-negative patients were screened and analyzed statistically. Univariate analysis showed uterine cavity HPV infection resulted in lower rates of ongoing pregnancy (31.5% vs. 44.6%; p = 0.023), implantation (32.3% vs. 43.1%; p = 0.026), biochemical pregnancy (47.8% vs. 62.5%; p = 0.010), and clinical pregnancy (40.2% vs. 54.3%; p = 0.015) compared with HPV negative group. The infertile female with positive HPV also had a slightly higher frequency of biochemical miscarriage (15.9% vs. 13.0%; p = 0.610) and clinical miscarriage (24.3% vs. 15.5%; p = 0.188). These findings suggest that HPV infection in the uterine cavity is a high risk for ART failure. HPV screening is recommended before ART treatment, which may be benefit to improving pregnancy outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Journal of medical virology - 96(2024), 3 vom: 28. Feb., Seite e29468 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bai, Mingzhu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Assisted reproductive technology |
|---|
| Anmerkungen: |
Date Completed 29.02.2024 Date Revised 29.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.29468 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369054261 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369054261 | ||
| 003 | DE-627 | ||
| 005 | 20240229235511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.29468 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM369054261 | ||
| 035 | |a (NLM)38415499 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bai, Mingzhu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assisted reproductive technology treatment failure and the detection of intrauterine HPV through spent embryo transfer media sample |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.02.2024 | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley Periodicals LLC. | ||
| 520 | |a Cervical human papillomavirus (HPV) infection is believed to increase the risks of pregnancy failure and abortion, however, whether the uterine cavity HPV infection reduces pregnancy rate or increases miscarriage rate remains unclarified in infertile women undergoing assisted reproductive technology (ART) treatment. Therefore, we aimed to assess ART outcomes in the presence of intrauterine HPV. This was a hospital-based multicenter (five reproductive medicine centers) matched cohort study. This study involved 4153 infertile women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection treatment in five reproductive medicine centers between October 2018 and 2020. The spent embryo transfer media sample with endometrium tissue were collected and performed with flow-through hybridization and gene chips to detect HPV DNA. According to basic characteristics, HPV-positive and negative patients were matched in a ratio of 1:4 by age, body mass index transfer timing, transfer type, and number of embryos transferred. The primary outcome was pregnancy and clinical miscarriage rates in the transfer cycle underwent HPV detection. 92 HPV-positive and 368 HPV-negative patients were screened and analyzed statistically. Univariate analysis showed uterine cavity HPV infection resulted in lower rates of ongoing pregnancy (31.5% vs. 44.6%; p = 0.023), implantation (32.3% vs. 43.1%; p = 0.026), biochemical pregnancy (47.8% vs. 62.5%; p = 0.010), and clinical pregnancy (40.2% vs. 54.3%; p = 0.015) compared with HPV negative group. The infertile female with positive HPV also had a slightly higher frequency of biochemical miscarriage (15.9% vs. 13.0%; p = 0.610) and clinical miscarriage (24.3% vs. 15.5%; p = 0.188). These findings suggest that HPV infection in the uterine cavity is a high risk for ART failure. HPV screening is recommended before ART treatment, which may be benefit to improving pregnancy outcome | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HPV | |
| 650 | 4 | |a assisted reproductive technology | |
| 650 | 4 | |a miscarriage | |
| 650 | 4 | |a pregnancy outcomes | |
| 650 | 4 | |a uterine cavity | |
| 700 | 1 | |a Sun, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Jinhui |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Mu |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Zhenya |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Suying |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zikai |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Wenxin |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Youji |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Shihua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhenbo |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Hong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 96(2024), 3 vom: 28. Feb., Seite e29468 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2024 |g number:3 |g day:28 |g month:02 |g pages:e29468 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29468 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2024 |e 3 |b 28 |c 02 |h e29468 | ||